WO1998021195A1 - Indene inhibitors of cox-2 - Google Patents

Indene inhibitors of cox-2 Download PDF

Info

Publication number
WO1998021195A1
WO1998021195A1 PCT/US1997/020231 US9720231W WO9821195A1 WO 1998021195 A1 WO1998021195 A1 WO 1998021195A1 US 9720231 W US9720231 W US 9720231W WO 9821195 A1 WO9821195 A1 WO 9821195A1
Authority
WO
WIPO (PCT)
Prior art keywords
carbon atoms
hydrogen
alkyl
halogen
fluoroalkoxy
Prior art date
Application number
PCT/US1997/020231
Other languages
English (en)
French (fr)
Inventor
Amedeo Arturo Failli
Original Assignee
American Home Products Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Products Corporation filed Critical American Home Products Corporation
Priority to JP52266398A priority Critical patent/JP2001504118A/ja
Priority to AU51055/98A priority patent/AU5105598A/en
Priority to CA002269035A priority patent/CA2269035A1/en
Priority to EP97945622A priority patent/EP0948493A1/en
Priority to BR9713346-9A priority patent/BR9713346A/pt
Publication of WO1998021195A1 publication Critical patent/WO1998021195A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/60—Two oxygen atoms, e.g. succinic anhydride
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • R 1 is hydrogen, halogen, alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, fluoroalkoxy of 1-6 carbon atoms, trifluoromethyl, alkylthio of 1-3 carbon atoms, or SCF3
  • R 2 and R 3 are each independently, hydrogen or alkyl of 1-6 carbon atoms, or R 2 and R 3 may be taken together to form a saturated cycloalkyl ring of 3-7 carbon atoms
  • R 4 , R 5 , R 6 , R 7 and R 8 are each independently, hydrogen, halogen, alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-3 carbon atoms, alkylsulfinyl of 1-3 carbon atoms, alkylsulfonyl of 1-3 carbon atoms, halogen, fluoroalkoxy of 1-6 carbon atoms, CF3, or SCF3.
  • Liquid carriers may be used in preparing solutions, suspensions, emulsions, syrups and elixirs.
  • the active ingredient of this invention can be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fat.
  • the liquid carrier can contain other suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers or osmo-regulators.
  • suitable examples of liquid carriers for oral and parenteral administration include water (particularly containing additives as above e.g.
  • cellulose derivatives preferably sodium carboxymethyl cellulose solution
  • alcohols including monohydric alcohols and polyhydric alcohols e.g. glycols
  • oils e.g. fractionated coconut oil and arachis oil
  • the carrier can also be an oily ester such as ethyl oleate and isopropyl myristate.
  • Sterile liquid carriers are used in sterile liquid form compositions for parenteral administration.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PCT/US1997/020231 1996-11-12 1997-11-10 Indene inhibitors of cox-2 WO1998021195A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP52266398A JP2001504118A (ja) 1996-11-12 1997-11-10 Ｃｏｘ―２のインデン阻害剤
AU51055/98A AU5105598A (en) 1996-11-12 1997-11-10 Indene inhibitors of cox-2
CA002269035A CA2269035A1 (en) 1996-11-12 1997-11-10 Indene inhibitors of cox-2
EP97945622A EP0948493A1 (en) 1996-11-12 1997-11-10 Indene inhibitors of cox-2
BR9713346-9A BR9713346A (pt) 1996-11-12 1997-11-10 Inibidores de indenos de cox - 2

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74794896A 1996-11-12 1996-11-12
US08/747,948 1996-11-12

Publications (1)

Publication Number Publication Date
WO1998021195A1 true WO1998021195A1 (en) 1998-05-22

Family

ID=25007366

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/020231 WO1998021195A1 (en) 1996-11-12 1997-11-10 Indene inhibitors of cox-2

Country Status (9)

Country Link
EP (1) EP0948493A1 (ko)
JP (1) JP2001504118A (ko)
KR (1) KR20000053227A (ko)
CN (1) CN1237162A (ko)
AU (1) AU5105598A (ko)
BR (1) BR9713346A (ko)
CA (1) CA2269035A1 (ko)
HU (1) HUP9904696A2 (ko)
WO (1) WO1998021195A1 (ko)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6649629B2 (en) 1999-12-23 2003-11-18 Nitromed, Inc. Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
US8044048B2 (en) 2006-01-04 2011-10-25 Southern Research Institute Derivatives of sulindac, use thereof and preparation thereof
US8541471B2 (en) 2003-05-07 2013-09-24 Osteologix A/S Water-soluble strontium salts for use in treatment of cartilage and/or bone conditions
WO2022195579A1 (en) 2021-03-15 2022-09-22 Saul Yedgar Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory diseases

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104592091B (zh) * 2015-01-27 2017-07-04 冉瑞琼 一种含吲哚乙酸核心结构的化合物及其应用
CA3235127A1 (en) * 2021-10-15 2023-04-20 Yao XU 2,3-dimethoxy-5-methyl-1,4-benzoquinone alkyl alcohol derivative and use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3647858A (en) * 1970-05-01 1972-03-07 Merck & Co Inc Process for preparing 1-benzylidene-3-indenyl acetic acids
US5420153A (en) * 1992-04-28 1995-05-30 American Home Products Corporation Tetronic, thiotetronic and tetramic acid derivatives as phospholipase A.sub.
EP0675103A2 (en) * 1994-03-01 1995-10-04 Scotia Holdings Plc Derivatives of essential fatty acids and nonsteroidal antiinflammatory drugs

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3647858A (en) * 1970-05-01 1972-03-07 Merck & Co Inc Process for preparing 1-benzylidene-3-indenyl acetic acids
US5420153A (en) * 1992-04-28 1995-05-30 American Home Products Corporation Tetronic, thiotetronic and tetramic acid derivatives as phospholipase A.sub.
EP0675103A2 (en) * 1994-03-01 1995-10-04 Scotia Holdings Plc Derivatives of essential fatty acids and nonsteroidal antiinflammatory drugs

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6649629B2 (en) 1999-12-23 2003-11-18 Nitromed, Inc. Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
US7166618B2 (en) 1999-12-23 2007-01-23 Nitromed, Inc. Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
US7432285B2 (en) 1999-12-23 2008-10-07 Nitromed, Inc. Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
US8541471B2 (en) 2003-05-07 2013-09-24 Osteologix A/S Water-soluble strontium salts for use in treatment of cartilage and/or bone conditions
US8044048B2 (en) 2006-01-04 2011-10-25 Southern Research Institute Derivatives of sulindac, use thereof and preparation thereof
WO2022195579A1 (en) 2021-03-15 2022-09-22 Saul Yedgar Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory diseases

Also Published As

Publication number Publication date
BR9713346A (pt) 2000-05-09
AU5105598A (en) 1998-06-03
CA2269035A1 (en) 1998-05-22
EP0948493A1 (en) 1999-10-13
KR20000053227A (ko) 2000-08-25
HUP9904696A2 (hu) 2000-05-28
CN1237162A (zh) 1999-12-01
JP2001504118A (ja) 2001-03-27

Similar Documents

Publication Publication Date Title
US5869524A (en) Indene inhibitors of COX-2
AU771668C (en) 1-(4-sulfamylaryl)-3-substituted-5-aryl-2-pyrazolines as inhibitors of cyclooxygenase-2
US5521213A (en) Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
US5698584A (en) 3,4-diaryl-2-hydroxy-2,5-dihydrofurans as prodrugs to COX-2 inhibitors
US5776967A (en) Pyranoindole inhibitors of COX--2
US5585504A (en) Process of making cox-2 inhibitors having a lactone bridge
US6057319A (en) 3,4-Diaryl-2-hydroxy-2,5-dihydrofurans as prodrugs to cox-2 inhibitors
JPH11500146A (ja) Ｃｏｘ−２インヒビターとしての（メチルスルホニル）フェニル−２−（５ｈ）−フラノン類
JPH11500748A (ja) Ｃｏｘ−２阻害剤のプロドラッグとしての３，４−ジアリール−２−ヒドロキシ−２，５−ジヒドロフラン
CN101910144B (zh) 对羟基苯丙烯酸衍生物及其应用
JPH0510347B2 (ko)
WO1998021195A1 (en) Indene inhibitors of cox-2
FR2521992A1 (fr) Nouveaux composes de pyridine utiles comme medicaments
JP2001514668A (ja) Ｃｏｘ−２阻害薬としての酸素連結部を有する（メチルスルホニル）フェニル−２−（５ｈ）−フラノン類
US5102905A (en) Thienyl benzothienyl and dibenzothienyl compounds as inhibitors of aldose reductase
US7122571B2 (en) Substituted hydrazones as inhibitors of cyclooxygenase-2
KR20000005146A (ko) 퓨란 디아릴메틸리덴 유도체, 이의 제조방법 및이를 함유하는약제학적 조성물
MXPA99004202A (en) Indene inhibitors of cox-2
WO2002059072A2 (en) 12-hydroxy-eicosatrienoic acid analogs and methods of use thereof
WO2008032665A1 (fr) Nouveau dérivé de l'acide phénylacétique
AU5620700A (en) (z)-styryl acetoxyphenyl sulfides as cyclooxygenase inhibitors
US3621037A (en) Benzofuran derivatives
JP2002212177A (ja) 脂質代謝改善剤
JPS62149672A (ja) ４Ｈ−ベンゾ〔４，５〕シクロヘプタ〔１，２−ｂ〕チオフエン誘導体
WO2000076983A1 (en) 1-(4-arylsulfonyl)-3-substituted-5-aryl-2-pyrazolines as inhibitors of cyclooxygenase-2

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97199655.5

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 51055/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 335224

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2269035

Country of ref document: CA

Ref document number: 2269035

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/1999/004202

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1997945622

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 1998 522663

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1019997004202

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1997945622

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1019997004202

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1997945622

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1019997004202

Country of ref document: KR